IDH2 and central nervous system cancer: Notably, mutations in IDH1 and IDH2 are well-characterized in lower-grade gliomas and secondary GBM, leading to the production of the oncometabolite 2-hydroxyglutarate (2-HG), which contributes to epigenetic dysregulation and tumorigenesis.